Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225589 · ClinicalTrials.gov registry record · Phase 3
A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
NCT00225589: Completed Phase 3 study, sponsored by AstraZeneca.
NCT00225589 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 840 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225589, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
Study Summary
The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
Interventions
- DRUG Rosuvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
What the finished NCT00225589 record still lists
NCT00225589 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin calcium is the first listed.
NCT00225589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00225589 about?
NCT00225589 is a clinical study titled "A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)". The purpose of this trial is to see if rosuvastatin will be effective in decreasing the thickness of the walls of the arteries in the neck for people who already have some evidence of thickening of these walls.
What is the current status of trial NCT00225589?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2002-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00225589?
The interventions under investigation include: Rosuvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00225589?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00225589's enrollment target sits among peer trials
840 392nd of 2000 higher than 1,607 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia